Import from '@/components/mdx'

Can I Take St. John's Wort with Tymlos (Abaloparatide)?

The Short Answer: Is This Combination Safe?

Probably yes, from a direct drug-interaction standpoint, but the full picture is more complicated. Abaloparatide is a synthetic analog of parathyroid hormone-related protein (PTHrP). After subcutaneous injection, it is broken down by nonspecific proteases, not by the cytochrome P450 enzyme family that St. John's Wort is known to induce. That means the classic CYP3A4-mediated drug interaction that makes St. John's Wort so problematic with medications like cyclosporine, warfarin, or oral contraceptives does not apply to Tymlos in the same direct way.

The concern is real but indirect. If you take other medications alongside Tymlos, or if you are still in your perimenopausal years and using hormonal contraception, St. John's Wort may create meaningful problems in your overall medication regimen, even if it does not directly alter abaloparatide blood levels.

What Abaloparatide Actually Does in Your Body

Tymlos is a 34-amino-acid peptide that selectively activates the PTH1 receptor, stimulating new bone formation. In the ACTIVE trial, 80 mcg subcutaneous daily reduced new vertebral fractures by 86% compared to placebo over 18 months, which was the key registration trial for the drug. After injection, abaloparatide reaches peak plasma concentration in about 30 to 60 minutes and has a half-life of roughly 1.7 hours. Clearance occurs primarily through proteolytic degradation and renal filtration, not hepatic CYP enzymes.

How St. John's Wort Disrupts Other Drugs

St. John's Wort's main active constituents, hyperforin and hypericin, strongly induce CYP3A4, CYP2C9, and P-glycoprotein (P-gp). A landmark pharmacokinetic study published in The Lancet demonstrated that St. John's Wort reduced cyclosporine area under the curve by approximately 50% through this induction mechanism. Drugs that are CYP3A4 substrates with narrow therapeutic windows, including certain anticonvulsants, antiretrovirals, and oral contraceptives, are genuinely at risk.

Because abaloparatide is a peptide, not a small-molecule CYP substrate, it bypasses this mechanism entirely.

Why Women on Tymlos Should Still Think Carefully About St. John's Wort

The pharmacokinetic interaction may be low risk, but women's health does not exist in a single-drug silo.

The Contraception Issue for Perimenopausal Women

Tymlos is approved only for postmenopausal women, but "postmenopausal" in clinical practice sometimes includes women in their late 40s or early 50s who have reached menopause early, or women who have had surgical menopause. If there is any residual fertility question or if your clinician has you using hormonal contraception for cycle regulation during the perimenopausal transition, St. John's Wort becomes directly relevant.

A Cochrane systematic review confirmed that St. John's Wort significantly reduces plasma concentrations of ethinyl estradiol and norethindrone, the most common oral contraceptive hormones. Breakthrough bleeding and unintended pregnancy have been reported in women taking both. If you are in this category, St. John's Wort poses a real, documented risk to your contraception reliability, even if it does not touch your abaloparatide levels.

Co-Medications Commonly Taken with Tymlos

Women with postmenopausal osteoporosis at high fracture risk rarely take Tymlos in isolation. Common co-medications include:

• Calcium and vitamin D supplements (no interaction with St. John's Wort)
• Selective serotonin reuptake inhibitors (SSRIs) for depression or vasomotor symptoms (major interaction: serotonin syndrome risk with St. John's Wort)
• Menopausal hormone therapy (MHT) such as estradiol patches or pills (St. John's Wort may reduce estrogen concentrations via CYP3A4 induction)
• Thyroid hormone replacement (levothyroxine), common in postmenopausal women (St. John's Wort may reduce absorption and increase clearance)
• Bisphosphonates used as sequential therapy after Tymlos discontinuation (no significant CYP interaction)

The FDA maintains an interaction table noting St. John's Wort as a strong inducer that can reduce plasma levels of CYP3A4-metabolized drugs by 50 to 90%. If you take an SSRI or MHT alongside Tymlos, the St. John's Wort interaction is with those medications, not with abaloparatide itself, but the clinical consequence still affects you.

The Serotonin Syndrome Warning

If your clinician has prescribed an SSRI or SNRI (sertraline, escitalopram, venlafaxine, and others) to manage depression, anxiety, or perimenopausal mood symptoms alongside Tymlos, do not add St. John's Wort. A case series and pharmacodynamic analysis published in the British Medical Journal documented serotonin syndrome in patients combining St. John's Wort with SSRIs, with symptoms including agitation, tremor, rapid heart rate, and in severe cases, hyperthermia. This is a pharmacodynamic, not pharmacokinetic, interaction, and it is serious.

Pharmacokinetics of Abaloparatide: The Sex-Specific Data

Women have been underrepresented in PK trials for many drugs. For abaloparatide, the ACTIVE trial enrolled only postmenopausal women, so the primary efficacy and safety data are entirely female. This is one area where the evidence base is actually stronger for women than for men.

The prescribing information filed with the FDA reports that the mean maximum plasma concentration (Cmax) of abaloparatide 80 mcg is approximately 812 pg/mL, with a time to peak of 0.51 hours and a terminal half-life of about 1.7 hours in postmenopausal women. Body weight modestly influences exposure. Women with lower body weight reach somewhat higher Cmax values, though the prescribing information does not recommend dose adjustment based on weight for the approved 80 mcg dose.

Renal impairment does increase abaloparatide exposure, so if you have reduced kidney function (common with aging), your clinician should know this before prescribing. No hepatic dosing adjustment is needed, which again reflects the peptide's non-CYP clearance pathway.

The WomanRx Interaction Assessment Framework for Peptide-Based Bone Therapies and Supplements

When evaluating any supplement alongside a peptide drug like abaloparatide or teriparatide, consider three separate questions rather than relying on a single CYP-based interaction lookup:

1. Does the supplement alter peptide absorption, distribution, or proteolytic clearance? (Rarely relevant for injected peptides.)
2. Does the supplement interact with your co-medications (SSRIs, MHT, thyroid hormones, anticoagulants)?
3. Does the supplement pharmacodynamically oppose or amplify the drug's mechanism? (For bone therapies, check whether the supplement affects calcium signaling, PTH receptor activity, or osteoblast function.)

This three-question check catches indirect interactions that single-drug lookup tools miss.

Pregnancy, Lactation, and Contraception: Required Reading

Tymlos is contraindicated in pregnancy. This needs to be stated plainly.

Abaloparatide is labeled FDA Pregnancy Category risk equivalent: animal studies showed fetal harm at doses above the clinical dose, and there are no adequate human pregnancy data. The FDA prescribing label states that Tymlos should not be used during pregnancy, and women of reproductive potential should use effective contraception during treatment.

Why This Matters Even for "Postmenopausal" Women

Menopause diagnosis requires 12 consecutive months without a menstrual period. Some women receive a diagnosis of early menopause or premature ovarian insufficiency (POI) in their 30s or 40s, and a subset of women with POI may experience intermittent ovarian activity and, rarely, spontaneous ovulation. If you are under 50 and have been told you are postmenopausal, discuss your reproductive status explicitly with your prescribing clinician before starting Tymlos.

St. John's Wort and Contraception Efficacy

Here is where the St. John's Wort question becomes urgent for younger postmenopausal or perimenopausal women. If you are using combined oral contraceptives or progestin-only pills as your contraceptive method:

St. John's Wort induces CYP3A4 and P-gp, accelerating the metabolism of ethinyl estradiol and synthetic progestins. A pharmacokinetic crossover study in healthy women showed that St. John's Wort at 300 mg three times daily reduced ethinyl estradiol AUC by approximately 13 to 15% and norethindrone AUC by about 13%, sufficient to increase breakthrough bleeding and reduce contraceptive reliability. Non-hormonal contraception (copper IUD, condoms) is not affected.

Lactation

Tymlos is not studied in lactating women. The prescribing label does not address breastfeeding safety. Because abaloparatide is a peptide, it is likely degraded in the infant gut if any transfer into breast milk occurs, but no human lactation data exist. Given that the indication (postmenopausal osteoporosis) does not overlap with lactation, this is primarily a theoretical concern. If you are postpartum and lactating and have been prescribed Tymlos off-label or through a non-standard pathway, discuss this gap openly with your clinician.

Who Should Not Take St. John's Wort While on Tymlos

Even though the direct pharmacokinetic interaction between St. John's Wort and abaloparatide is low-risk, certain groups of women should avoid the combination entirely.

Avoid If You Are Taking SSRIs or SNRIs

Serotonin syndrome is rare but dangerous. Combining St. John's Wort with any serotonergic antidepressant creates additive serotonergic activity. Given that postmenopausal women are commonly prescribed SSRIs for vasomotor symptoms, mood, and general depression, this is not a rare scenario. If you need support for low mood, ask your clinician about evidence-based non-supplement options.

Avoid If You Are on MHT

Menopausal hormone therapy (estradiol, either oral or transdermal, often paired with a progestogen) is metabolized in part through CYP3A4. St. John's Wort may reduce circulating estradiol concentrations, potentially diminishing the efficacy of MHT for hot flashes, bone protection, and urogenital symptoms. The NAMS 2022 Hormone Therapy Position Statement notes that CYP3A4 inducers can meaningfully alter estrogen exposure in women using oral estrogen, which is relevant if your MHT is oral rather than transdermal.

Transdermal estradiol bypasses first-pass hepatic metabolism, so CYP3A4 induction has less impact on transdermal formulations than on oral ones. This is a practical distinction worth knowing.

Avoid If You Take Levothyroxine

Hypothyroidism is extremely common in postmenopausal women. A study in the journal Clinical Pharmacokinetics found that St. John's Wort can reduce levothyroxine exposure, potentially worsening hypothyroid symptoms and altering thyroid-stimulating hormone (TSH) levels. If your clinician is managing your thyroid alongside your bone therapy, adding St. John's Wort without disclosure could destabilize a well-controlled thyroid regimen.

What Women Commonly Use St. John's Wort For (and Evidence-Based Alternatives)

Many postmenopausal women reach for St. John's Wort because of low mood, mild depression, or anxiety that accompanies the hormonal shifts of menopause. The desire is understandable. The evidence for St. John's Wort in mild to moderate depression is reasonably good: a 2008 Cochrane review of 29 trials found St. John's Wort superior to placebo and similarly effective to standard antidepressants for mild to moderate depression, with fewer side effects.

The problem is not that St. John's Wort lacks evidence for mood. The problem is its interaction profile with the rest of your regimen.

Alternatives Worth Discussing with Your Clinician

• For low mood in perimenopause or postmenopause: MHT has strong evidence for improving mood in women with depressive symptoms related to hormonal change. The ACOG Clinical Practice Bulletin on managing menopausal symptoms supports MHT for vasomotor symptoms and notes mood benefits in symptomatic women.
• For mild anxiety or sleep disruption: Cognitive behavioral therapy for insomnia (CBT-I) has strong evidence without drug interactions.
• For general well-being during the menopause transition: Regular resistance exercise has documented benefits for bone density, mood, and metabolic health, and it has zero drug interactions.

Monitoring If You Are Already Taking Both

If you are reading this because you are already taking St. John's Wort alongside Tymlos, do not stop either abruptly without speaking to your clinician first. Abruptly stopping Tymlos is not dangerous in the way discontinuing some medications is, but you do need a sequential therapy plan after Tymlos completion to preserve bone gains. Abruptly stopping St. John's Wort can cause discontinuation symptoms including irritability and low mood.

Steps to take:

1. Tell your prescribing clinician or pharmacist you are taking St. John's Wort. This is not a judgment. It is a safety-critical disclosure.
2. Ask for a full medication review. The St. John's Wort interaction is most likely to affect your co-medications, not the abaloparatide itself.
3. Check your TSH if you take levothyroxine. A six- to eight-week TSH recheck after starting or stopping St. John's Wort is reasonable.
4. If you take an SSRI, tell your clinician immediately. Serotonin syndrome can develop within hours of adding a serotonergic supplement to an SSRI.
5. If you use hormonal contraception and are not yet certain you are fully postmenopausal, switch to non-hormonal contraception or confirm method reliability with your clinician.

What We Do Not Know: The Evidence Gap

No randomized controlled trial has directly studied the combination of abaloparatide and St. John's Wort. The conclusion that direct PK interaction is unlikely rests on known pharmacology (peptide metabolism, not CYP clearance) rather than on a direct human study. This distinction matters. Extrapolation from mechanism is reasonable but is not the same as direct evidence.

Women are also underrepresented in pharmacokinetic studies of supplements generally. Most St. John's Wort pharmacokinetic interaction studies have enrolled mixed-sex populations with small female subgroups, which limits how confidently we can apply those numbers to postmenopausal women specifically. Hormonal status (postmenopausal vs. Reproductive-age) affects CYP3A4 enzyme activity, and this is underexplored in the supplement-interaction literature.

The Bigger Picture: Osteoporosis Risk Is Serious, and So Is Your Regimen

Tymlos is not a casual prescription. It is reserved for women at high fracture risk, typically defined as a prior fragility fracture, a bone mineral density T-score of <-2.5 at the hip or spine, or a FRAX 10-year fracture probability above a clinician-defined threshold. The ACTIVE trial showed that abaloparatide reduced nonvertebral fracture risk by 43% compared to placebo over 18 months. Getting maximum benefit from that treatment depends on consistent daily dosing, adequate calcium and vitamin D, and a medication environment where nothing is undermining your co-medications.

A supplement that does not directly interact with abaloparatide can still compromise your treatment if it destabilizes your MHT, your antidepressant, or your thyroid medication.